Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor
In: Journal of Gastroenterology and Hepatology, Jg. 35 (2019-11-21), S. 1042-1048
Online
unknown
Zugriff:
Background and aim Because of their survival benefits, immune checkpoint inhibitors (ICIs) are widely administered to patients with various advanced-stage malignancies. During ICI treatment, drug-induced liver injury (DILI) occasionally occurs. In particular, hepatic immune-related adverse events (irAEs) are rare but serious and fatal. In patients with hepatic irAEs, immediate steroid treatment is generally recommended; however, the risk factors for ICI-associated DILI remain unknown. In the present study, we identified a risk factor for ICI-associated DILI. Methods We retrospectively analyzed 135 patients treated with anti-programmed cell death-1 (PD-1) antibodies, such as nivolumab and pembrolizumab, at Asahikawa Medical University Hospital. We investigated grade ≥ 2 hepatotoxic AEs during anti-PD-1 therapy, and PD-1 inhibitor-associated DILI was then diagnosed according to the Digestive Disease Week Japan (DDW-J) 2004 scale. The risk factors for PD-1 inhibitor-associated DILI were identified by Cox hazard analysis. Results Thirty-six patients developed grade ≥ 2 hepatic AEs during anti-PD-1 therapy. Among them, eight patients were diagnosed with PD-1 inhibitor-associated DILI based on the DDW-J 2004 scale. Cox hazard analysis revealed that non-alcoholic fatty liver disease (NAFLD) was a risk factor for PD-1 inhibitor-associated DILI. In addition, we revealed that the outcomes of patients with the DDW-J 2004 score = 3 were improved without steroid treatment. Conclusions NAFLD is a potential risk factor for PD-1 inhibitor-associated DILI based on the DDW-J 2004 scale. The DDW-J 2004 scale might be useful for determining whether steroid treatment is required in patients with PD-1 inhibitor-associated DILI.
Titel: |
Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor
|
---|---|
Autor/in / Beteiligte Person: | Fujiya, Mikihiro ; Sawada, Koji ; Hasebe, Takumu ; Okumura, Toshikatsu ; Nakajima, Shunsuke ; Hayashi, Hidemi |
Link: | |
Zeitschrift: | Journal of Gastroenterology and Hepatology, Jg. 35 (2019-11-21), S. 1042-1048 |
Veröffentlichung: | Wiley, 2019 |
Medientyp: | unknown |
ISSN: | 1440-1746 (print) ; 0815-9319 (print) |
DOI: | 10.1111/jgh.14889 |
Schlagwort: |
|
Sonstiges: |
|